Michael H. Davidson
Director; Director, Chief Executive Officer · 4 filings · Latest: Sep 14, 2026
BioAge Labs, Inc.
NewAmsterdam Pharma Co N.V.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Sep 14, 2026 | Purchase | $22.65 | 10,000 | $226.5K | 792,923 | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Mar 2, 2026 | Sale | $33.25 | 443,707 | $14.8M | 174,144 | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Mar 2, 2026 | Option Exercise | — | 443,707 | — | 617,851 | |
NAMS | Michael H. Davidson | — | Mar 2, 2026 | Proposed Sale | $35.46 | 443,707 | $15.7M | — | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Feb 26, 2026 | Sale | $33.71 | 183,332 | $6.2M | 174,144 | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Feb 26, 2026 | Option Exercise | — | 183,332 | — | 643,191 | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Feb 25, 2026 | Sale | $35.30 | 58,253 | $2.1M | 459,859 | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Feb 25, 2026 | Option Exercise | — | 58,253 | — | 518,112 | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Feb 24, 2026 | Sale | $36.15 | 64,708 | $2.3M | 459,859 | |
NAMS | Michael H. Davidson | Director, Chief Executive Officer | Feb 24, 2026 | Option Exercise | — | 64,708 | — | 524,567 | |
NAMS | Michael H. Davidson | — | Feb 24, 2026 | Proposed Sale | $36.17 | 750,000 | $27.1M | — | |
NAMS | Michael Davidson | — | Jan 7, 2026 | Proposed Sale | $35.48 | 11,582 | $410.9K | — | |
NAMS | Michael H. Davidson | — | Mar 26, 2025 | Proposed Sale | $23.41 | 12,258 | $287.0K | — |